Trevi Therapeutics, Inc. (TRVI)Healthcare | Biotechnology | New Haven, United States | NasdaqGM
12.29 USD
-0.64
(-4.950%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:14 a.m. EDT
Trevi Therapeutics presents a classic biotech dichotomy: a fortress-like balance sheet funding a high-stakes drug development race, yet priced as a speculative lottery ticket. Fundamentally, the company is in an exceptional position with negligible debt ($605k) and a massive cash hoard ($319M), providing ample runway to execute its chronic cough trial for millions of patients. The stock has delivered a spectacular +200% return over the last six years, driven by a massive surge in 2025, though recent price action shows the market taking profits as the stock trades well above its 50-day average. The lack of a dividend is appropriate for a growth-stage biotech reinvesting all capital into R&D. While the statistical forecast model offers no directional signal, the options market reveals a polarized sentiment: traders are buying deep OTM calls and puts, betting on binary outcomes rather than steady appreciation. This creates a high-risk environment where the thesis relies entirely on the success of the upcoming clinical data. For investors, this is a hold-or-watch scenario; the fundamentals are sound enough to survive, but the valuation leaves little room for error if the trial results are merely 'promising' rather than transformative. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.068477 |
| AutoETS | 0.069468 |
| AutoARIMA | 0.069618 |
| AutoTheta | 0.127838 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 6.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.071 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.188 |
| Market Cap | 1,751,028,096 |
| Forward P/E | -21.30 |
| Beta | 0.98 |
| Website | https://www.trevitherapeutics.com |
As of Oct. 10, 2026, 9:14 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. Call Open Interest is heavily skewed out-of-the-money (OTM) at strikes like $17 and $18, suggesting a hope for a massive biotech-style spike. Conversely, Put Open Interest is concentrated OTM at $19 and deep ITM at $10, indicating a hedge against a crash or a 'lottery ticket' strategy where traders buy cheap puts hoping for a downside event while holding long-dated calls. The imbalance in volume vs open interest on specific strikes (e.g., $19 puts) suggests active trading of speculative positions rather than static hedging.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2688911 |
| Address1 | 195 Church Street |
| Address2 | 16th Floor |
| All Time High | 20.22 |
| All Time Low | 0.46 |
| Ask | 23.73 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 3,823,540 |
| Average Daily Volume3 Month | 2,097,904 |
| Average Volume | 2,097,904 |
| Average Volume10Days | 3,823,540 |
| Beta | 0.984 |
| Bid | 13.61 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 2.257 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.29 |
| Current Ratio | 37.283 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 13.19 |
| Day Low | 12.29 |
| Debt To Equity | 0.188 |
| Display Name | Trevi Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -59,420,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -24.112 |
| Enterprise Value | 1,432,763,136 |
| Eps Current Year | -0.479 |
| Eps Forward | -0.577 |
| Eps Trailing Twelve Months | -0.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.2618 |
| Fifty Day Average Change | -3.9718008 |
| Fifty Day Average Change Percent | -0.24424115 |
| Fifty Two Week Change Percent | 26.88911 |
| Fifty Two Week High | 20.22 |
| Fifty Two Week High Change | -7.9299994 |
| Fifty Two Week High Change Percent | -0.39218593 |
| Fifty Two Week Low | 9.28 |
| Fifty Two Week Low Change | 3.0100002 |
| Fifty Two Week Low Change Percent | 0.3243535 |
| Fifty Two Week Range | 9.28 - 20.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,235,800,000 |
| Float Shares | 118,088,251 |
| Forward Eps | -0.577 |
| Forward P E | -21.299826 |
| Free Cashflow | -33,282,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 34 |
| Fullday Change | -0.64000034 |
| Fullday Change Percent | -4.9497313 |
| Fullday Price | 12.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0062800003 |
| Held Percent Institutions | 1.07709 |
| Implied Shares Outstanding | 142,475,841 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut. |
| Long Name | Trevi Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,751,028,096 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_225357348 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -51,107,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,060,200,660 |
| Number Of Analyst Opinions | 11 |
| Open | 12.86 |
| Operating Cashflow | -52,629,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 203 304 2499 |
| Previous Close | 12.93 |
| Price Eps Current Year | -25.65762 |
| Price Hint | 2 |
| Price To Book | 5.4452815 |
| Profit Margins | 0.0 |
| Quick Ratio | 36.684 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.18182 |
| Region | US |
| Regular Market Change | -0.64 |
| Regular Market Change Percent | -4.94973 |
| Regular Market Day High | 13.19 |
| Regular Market Day Low | 12.29 |
| Regular Market Day Range | 12.29 - 13.19 |
| Regular Market Open | 12.86 |
| Regular Market Previous Close | 12.93 |
| Regular Market Price | 12.29 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 1,573,433 |
| Return On Assets | -0.13816 |
| Return On Equity | -0.19657 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 142,475,841 |
| Shares Percent Shares Out | 0.1027 |
| Shares Short | 14,639,150 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 12,012,371 |
| Short Name | Trevi Therapeutics, Inc. |
| Short Percent Of Float | 0.1141 |
| Short Ratio | 9.1 |
| Source Interval | 15 |
| State | CT |
| Symbol | TRVI |
| Target High Price | 40.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 28.18182 |
| Target Median Price | 25.0 |
| Total Cash | 318,870,016 |
| Total Cash Per Share | 2.238 |
| Total Debt | 605,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.2829 |
| Two Hundred Day Average Change | -1.9928999 |
| Two Hundred Day Average Change Percent | -0.13953048 |
| Type Disp | Equity |
| Volume | 1,573,433 |
| Website | https://www.trevitherapeutics.com |
| Zip | 6,510 |